UT MD Anderson Cancer Center
Eric Jonasch, MD is Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Center at the University of Texas M. D. Anderson Cancer Center in Houston, Texas.
Dr. Jonasch is director of the VHL Clinical Center at the MD Anderson Cancer Center and is involved in tissue-based translational research in renal cell carcinoma and VHL disease. He heads a number of investigator-initiated clinical trials and leads the Department of Defense Kidney Cancer Research Consortium. Dr. Jonasch is in charge on an ongoing laboratory research effort evaluating the determinants of response and resistance to therapy in renal cell carcinoma and VHL disease. Dr. Jonasch’s current work focuses on understanding the drivers of renal cell carcinoma tumor ontogeny, and the development of informative models of tumor-microenvironmental interaction. Dr. Jonasch serves as Vice-Chair of the NCCN Kidney Cancer Guideline Panel and is a Board member of the International Kidney Cancer Coalition.
Aravive (Individual(s) Involved: Self; Clinical Condition: RCC): Consultant; Arrowhead (Individual(s) Involved: Self): Grant/Research Support; Aveo (Individual(s) Involved: Self; Clinical Condition: RCC): Consultant; Calithera Biosciences (Individual(s) Involved: Self; Clinical Condition: RCC): Consultant; Eisai, (Individual(s) Involved: Self; Clinical Condition: RCC): Consultant; Exelixis (Individual(s) Involved: Self; Clinical Condition: RCC): Consultant; Ipsen (Individual(s) Involved: Self): Consultant; Merck & Co., Inc. (Individual(s) Involved: Self; Clinical Condition: RCC, VHL disease): Consultant, Grant/Research Support; Natera (Individual(s) Involved: Self): Consultant; NiKang (Individual(s) Involved: Self; Clinical Condition: RCC): Consultant, Grant/Research Support; Takeda Pharmaceutical Company Ltd (Individual(s) Involved: Self): Consultant
Thursday, September 29, 2022
9:40 AM – 11:50 AM
Thursday, September 29, 2022
10:45 AM – 11:05 AM
Thursday, September 29, 2022
11:25 AM – 11:50 AM